Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Categories: @vaccine-makers   

Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Website: jnj.com


  • Good financial results growth rate 42.8% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (16.4%)
  • Dividend yield for the last twelve months 2.5%
  • Free cash flow yield -1.8% (LTM)
  • Share price is 46.2% higher than minimum and 5.0% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (14.7x vs
    )
  • Fundamental value created in LTM (estimate)

Key Financials (Download financials)

Ticker: JNJ
Share price, USD:  (0.0%)207.63
year average price 173.63  


year start price 146.64 2025-01-23

min close price 146.36 2025-05-14

max close price 218.66 2026-01-17

current price 207.63 2026-01-22
Common stocks: 2 631 399 832

Dividend Yield:  2.5%
FCF Yield LTM: -1.8%
EV / LTM EBITDA: 14.7x
EV / EBITDA annualized: 15.5x
Last revenue growth (y/y):  +6.8%
Last growth of EBITDA (y/y):  +78.8%
Historical revenue growth:  +2.3%
Historical growth of EBITDA:  +30.5%
Target EV / EBITDA (hist percentile):
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 546 358
Net Debt ($m): 27 233
EV (Enterprise Value): 573 591
EBITDA LTM ($m): 38 890
EV / LTM EBITDA: 14.7x
Price to Book: 7.2x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2026-01-21globenewswire.com

Plaintiffs' Evidence Will Be Heard in Cases Alleging J&J's Talc Products Caused Women's Ovarian Cancer, Announced Levin Papantonio Attorney Chris Tisi

2026-01-21fool.com

Is This Dividend King Stock a Buy After a Major Development?

2026-01-21pymnts.com

Johnson & Johnson Says Product Launches, Regulatory Approvals Drive Growth

2026-01-21zacks.com

Johnson & Johnson (JNJ) Reports Q4 Earnings: What Key Metrics Have to Say

2026-01-21zacks.com

Johnson & Johnson (JNJ) Tops Q4 Earnings and Revenue Estimates

2026-01-21seekingalpha.com

Johnson & Johnson (JNJ) Q4 2025 Earnings Call Transcript

2026-01-21proactiveinvestors.com

AtaiBeckley seen as key beneficiary of Spravato's strong growth: Jefferies

2026-01-21zacks.com

J&J Stock Down Despite Q4 Earnings Beat, Oncology Drugs Drive Sales

2026-01-21proactiveinvestors.com

Johnson & Johnson reports Q4 earnings beat, issues 2026 guidance above forecasts

2026-01-21investopedia.com

5 Things to Know Before the Stock Market Opens
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data